Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells

Cancer Letters

Volumn 301, Issue 1, 2011, Pages 47-56

  Munoz Gamez J A ^a   Quiles Perez R ^a,b   Ruiz Extremera, A ^a,b   Martin Alvarez A B ^a   Sanjuan Nuñez, Laura ^c   Carazo, A ^a   León, Josefa ^a,b   Oliver, F J ^d   Salmeron J ^a,b  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Antineoplastic therapy; Cell death; DNA repair; Hepatocellular carcinoma; PARP 1; Transcriptional regulation

Indexed keywords

4 AMINO 1,8 NAPHTHALIMIDE; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN BCL XL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

EID: 78650556334     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.10.026     Document Type: Article

References (37)

1. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., Durnez A., Demetris A.J., Thorgeirsson S.S. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
2. Chen X.P., Qiu F.Z., Wu Z.D., Zhang Z.W., Huang Z.Y., Chen Y.F. Long-term outcome of resection of large hepatocellular carcinoma. Br. J. Surg. 2006, 93:600-606.
3. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
4. Madhusudan S., Middleton M.R. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev. 2005, 31:603-617.
5. Cohen-Armon M., Visochek L., Rozensal D., Kalal A., Geistrikh I., Klein R., Bendetz-Nezer S., Yao Z., Seger R. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol. Cell 2007, 25:297-308.
6. Peralta-Leal A., Rodriguez-Vargas J.M., Aguilar-Quesada R., Rodriguez M.I., Linares J.L., de Almodovar M.R., Oliver F.J. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic. Biol. Med. 2009, 47:13-26.
7. Aguilar-Quesada R., Munoz-Gamez J.A., Martin-Oliva D., Peralta-Leal A., Quiles-Perez R., Rodriguez-Vargas J.M., de Almodovar M.R., Conde C., Ruiz-Extremera A., Oliver F.J. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr. Med. Chem. 2007, 14:1179-1187.
8. Quiles-Perez R., Munoz-Gamez J.A., Ruiz-Extremera A., O'Valle F., Sanjuan-Nunez L., Martin-Alvarez A.B., Martin-Oliva D., Caballero T., Munoz de Rueda P., Leon J., Gonzalez R., Muntane J., Oliver F.J., Salmeron J. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010, 51:255-266.
9. Xu X.L., Xing B.C., Han H.B., Zhao W., Hu M.H., Xu Z.L., Li J.Y., Xie Y., Gu J., Wang Y., Zhang Z.Q. The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis 2010, 31:167-174.
10. Shimizu S., Nomura F., Tomonaga T., Sunaga M., Noda M., Ebara M., Saisho H. Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance. Oncol. Rep. 2004, 12:821-825.
11. Tentori L., Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. 2005, 52:25-33.
12. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
13. Russo A.L., Kwon H.C., Burgan W.E., Carter D., Beam K., Weizheng X., Zhang J., Slusher B.S., Chakravarti A., Tofilon P.J., Camphausen K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin. Cancer Res. 2009, 15:607-612.
14. Shah R.G., Ghodgaonkar M.M., el Affar B., Shah G.M. DNA vector-based RNAi approach for stable depletion of poly(ADP-ribose) polymerase-1. Biochem. Biophys. Res. Commun. 2005, 331:167-174.
15. Munoz-Gamez J.A., Martin-Oliva D., Aguilar-Quesada R., Canuelo A., Nunez M.I., Valenzuela M.T., Ruiz de Almodovar J.M., De Murcia G., Oliver F.J. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem. J. 2005, 386:119-125.
16. Stilmann M., Hinz M., Arslan S.C., Zimmer A., Schreiber V., Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol. Cell 2009, 36:365-378.
17. Tovar V., Villanueva A., Llovet J.M. Cell biology and genetics in liver cancer. Gastroenterol. Hepatol. 2007, 30:360-369.
18. Albert J.M., Cao C., Kim K.W., Willey C.D., Geng L., Xiao D., Wang H., Sandler A., Johnson D.H., Colevas A.D., Low J., Rothenberg M.L., Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 2007, 13:3033-3042.
19. Sabisz M., Wesierska-Gadek J., Skladanowski A. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. Biochem. Pharmacol. 2010, 79:1387-1397.
20. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
21. Pacher P., Liaudet L., Mabley J.G., Cziraki A., Hasko G., Szabo C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int. J. Mol. Med. 2006, 17:369-375.
22. Racz I., Tory K., Gallyas F., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., Literati-Nagy P. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 2002, 63:1099-1111.
23. Mota R.A., Hernandez-Espinosa D., Galbis-Martinez L., Ordonez A., Minano A., Parrilla P., Vicente V., Corral J., Yelamos J. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury. Crit. Care Med. 2008, 36:526-534.
24. Gero D., Szabo C. Role of the peroxynitrite-poly (ADP-ribose) polymerase pathway in the pathogenesis of liver injury. Curr. Pharm. Des. 2006, 12:2903-2910.
25. Mota R., Sanchez-Bueno F., Berenguer-Pina J.J., Hernandez-Espinosa D., Parrilla P., Yelamos J. Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury. Br. J. Pharmacol. 2007, 151:998-1005.
26. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54:375-429.
27. Cuzzocrea S. Shock, inflammation and PARP. Pharmacol. Res. 2005, 52:72-82.
28. Jagtap P., Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 2005, 4:421-440.
29. Kraus W.L. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr. Opin. Cell Biol. 2008, 20:294-302.
30. Ogino H., Nozaki T., Gunji A., Maeda M., Suzuki H., Ohta T., Murakami Y., Nakagama H., Sugimura T., Masutani M. Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics 2007, 8:41.
31. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
32. Breuhahn K., Longerich T., Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25:3787-3800.
33. Barnett J.C., Bean S.M., Nakayama J.M., Kondoh E., Murphy S.K., Berchuck A. High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. Obstet Gynecol. 2010, 115:49-54.
34. Nozaki T., Fujihara H., Watanabe M., Tsutsumi M., Nakamoto K., Kusuoka O., Kamada N., Suzuki H., Nakagama H., Sugimura T., Masutani M. Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci. 2003, 94:497-500.
35. Tong W.M., Cortes U., Hande M.P., Ohgaki H., Cavalli L.R., Lansdorp P.M., Haddad B.R., Wang Z.Q. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res. 2002, 62:6990-6996.
36. Martin-Oliva D., Aguilar-Quesada R., O'Valle F., Munoz-Gamez J.A., Martinez-Romero R., Garcia Del Moral R., Ruiz de Almodovar J.M., Villuendas R., Piris M.A., Oliver F.J. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006, 66:5744-5756.
37. Ogawa K., Masutani M., Kato K., Tang M., Kamada N., Suzuki H., Nakagama H., Sugimura T., Shirai T. Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline in mice. Cancer Lett. 2006, 236:32-38.